CY1113598T1 - Θερμοδυναμικα σταθερη μορφη του αλατος τολουολοσουλφονικου οξεος βαυ 43-9006 - Google Patents

Θερμοδυναμικα σταθερη μορφη του αλατος τολουολοσουλφονικου οξεος βαυ 43-9006

Info

Publication number
CY1113598T1
CY1113598T1 CY20121100767T CY121100767T CY1113598T1 CY 1113598 T1 CY1113598 T1 CY 1113598T1 CY 20121100767 T CY20121100767 T CY 20121100767T CY 121100767 T CY121100767 T CY 121100767T CY 1113598 T1 CY1113598 T1 CY 1113598T1
Authority
CY
Cyprus
Prior art keywords
acid salt
stable form
thermodynamic stable
toluolsulfonic acid
amino
Prior art date
Application number
CY20121100767T
Other languages
English (en)
Inventor
Alfons Grunenberg
Jana Lenz
Original Assignee
Bayer Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35482258&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113598(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma Aktiengesellschaft filed Critical Bayer Pharma Aktiengesellschaft
Publication of CY1113598T1 publication Critical patent/CY1113598T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Paper (AREA)
  • Catalysts (AREA)
  • Glass Compositions (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μία νέα μορφή, θερμοδυναμικά σταθερή σε θερμοκρασία δωματίου, του άλατος τολουολοσουλφονικού οξέος του 4-{4-[({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλ]αμινο}καρβονυλ)αμινο]φαινοξυ}-Ν-μεθυλοπυριδινο-2-καρβοξαμιδίου, στις διαδικασίες για την παρασκευή του, στα φάρμακα που το περιλαμβάνουν και στην χρήση του στον έλεγχο των διαταραχών.
CY20121100767T 2004-09-29 2012-08-24 Θερμοδυναμικα σταθερη μορφη του αλατος τολουολοσουλφονικου οξεος βαυ 43-9006 CY1113598T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023130 2004-09-29
EP05797740A EP1797038B1 (en) 2004-09-29 2005-09-20 Thermodynamically stable form of bay 43-9006 tosylate

Publications (1)

Publication Number Publication Date
CY1113598T1 true CY1113598T1 (el) 2016-06-22

Family

ID=35482258

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100767T CY1113598T1 (el) 2004-09-29 2012-08-24 Θερμοδυναμικα σταθερη μορφη του αλατος τολουολοσουλφονικου οξεος βαυ 43-9006

Country Status (33)

Country Link
US (1) US8877933B2 (el)
EP (1) EP1797038B1 (el)
JP (2) JP5215666B2 (el)
KR (4) KR20090018224A (el)
CN (1) CN101065360B (el)
AR (1) AR051301A1 (el)
AU (1) AU2005289100B2 (el)
BR (1) BRPI0515946A (el)
CA (1) CA2581843C (el)
CU (1) CU20070068A7 (el)
CY (1) CY1113598T1 (el)
DK (1) DK1797038T3 (el)
EC (1) ECSP077356A (el)
ES (1) ES2387812T3 (el)
GT (1) GT200500270A (el)
HK (1) HK1114605A1 (el)
HN (1) HN2005000722A (el)
HR (1) HRP20120662T1 (el)
IL (1) IL181734A (el)
MA (1) MA28880B1 (el)
MY (1) MY176929A (el)
NO (1) NO344272B1 (el)
NZ (1) NZ553804A (el)
PE (3) PE20060699A1 (el)
PL (1) PL1797038T3 (el)
PT (1) PT1797038E (el)
SG (1) SG155996A1 (el)
SI (1) SI1797038T1 (el)
TW (1) TWI382016B (el)
UA (1) UA91520C2 (el)
UY (1) UY29144A1 (el)
WO (1) WO2006034797A1 (el)
ZA (1) ZA200702510B (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US10653684B2 (en) 2002-02-11 2020-05-19 Bayer Healthcare Llc Aryl ureas with angiogenisis inhibiting activity
PT1478358E (pt) 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
KR20090018224A (ko) 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
US20090068146A1 (en) * 2005-10-31 2009-03-12 Scott Wilhelm Diaryl ureas and combinations
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
CN101220024A (zh) * 2007-12-11 2008-07-16 杜晓敏 一组抑制激酶的抗癌化合物
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
WO2009106825A1 (en) * 2008-02-27 2009-09-03 Cipla Limited Polymorphs of sorafenib and salts thereof
WO2010079498A2 (en) * 2009-01-12 2010-07-15 Hetero Research Foundation Novel polymorph of sorafenib tosylate
WO2010119306A1 (en) * 2009-04-15 2010-10-21 Fondazione Irccs Istituto Nazionale Dei Tumori Use of multi-kinase inhibitors in the treatment of vascular hyperpermeability
EP2440531A2 (en) * 2009-06-12 2012-04-18 Ratiopharm GmbH Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methyl-pyridine-2-carboxamide
US8604208B2 (en) 2009-09-24 2013-12-10 Ranbaxy Laboratories Limited Polymorphs of sorafenib acid addition salts
EP2480534A1 (en) 2009-09-24 2012-08-01 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
EP2499116A1 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Sorafenib ethylsulfonate salt, process for preparation and use
WO2011076711A2 (en) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphs of 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide
AU2011210326B2 (en) 2010-01-29 2014-10-09 Sun Pharmaceutical Industries Limited Sorafenib dimethyl sulphoxide solvate
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
PE20140165A1 (es) 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
WO2012071425A1 (en) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Solid state forms of sorafenib besylate, and processes for preparations thereof
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物
EP2559431A1 (en) 2011-08-17 2013-02-20 Ratiopharm GmbH Pharmaceutical composition comprising 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
EP2806860B1 (en) 2012-01-23 2023-04-19 Sandoz AG Pharmaceutical composition containing crystalline sorafenib tosylate
US9156789B2 (en) 2012-05-21 2015-10-13 Hetero Research Foundation Process for sorafenib tosylate polymorph III
EP2922820A4 (en) * 2012-05-23 2016-06-01 Shilpa Medicare Ltd PROCESS FOR PREPARING CRYSTALLINE SORAFENIB TOSYLATE
CN103570613B (zh) * 2012-07-18 2016-06-15 苏州泽璟生物制药有限公司 氘代ω-二苯基脲或其盐的多晶型物
CN103896833B (zh) * 2012-12-27 2016-12-28 上海创诺制药有限公司 索拉非尼对甲苯磺酸盐溶剂化物多晶型物及其制法和用途
WO2014118807A1 (en) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited A novel process for the preparation of sorafenib tosylate form iii
WO2014138905A1 (en) * 2013-03-14 2014-09-18 Apotex Technologies Inc. Forms of sorafenib tosylate and processes for the preparation thereof
WO2014181549A1 (ja) 2013-05-10 2014-11-13 株式会社デンソー 燃料噴射制御装置および燃料噴射システム
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
US20170114323A1 (en) * 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
RU2568638C1 (ru) * 2015-02-26 2015-11-20 Индивидуальный предприниматель Михайлов Олег Ростиславович КРИСТАЛЛИЧЕСКАЯ β-МОДИФИКАЦИЯ 4-[4-({ [4-ХЛОРО-3-(ТРИФТОРОМЕТИЛ) ФЕНИЛ]КАРБАМОИЛ} АМИНО)ФЕНОКСИ]-N-МЕТИЛ-ПИРИДИН-2-КАРБОКСАМИДА п-ТОЛУОЛСУЛЬФОНАТА, СПОСОБ ЕЁ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЁ ОСНОВЕ
EP3109236B1 (en) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Scalable process for the preparation of sorafenib tosylate ethanol solvate and sorafenib tosylate form iii
CN106336377A (zh) * 2015-07-17 2017-01-18 苏州亚宝药物研发有限公司 一种甲苯磺酸索拉非尼晶型ⅱ的制备方法
CN105503715A (zh) * 2015-12-03 2016-04-20 神威药业集团有限公司 一种索拉非尼半甲苯磺酸盐多晶型及其制备方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107759517A (zh) * 2016-08-23 2018-03-06 广州白云山医药集团股份有限公司白云山制药总厂 一种甲苯磺酸索拉非尼晶型ⅰ的制备方法
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN108164459B (zh) * 2016-12-07 2021-07-27 上海创诺制药有限公司 甲苯磺酸索拉非尼晶型iii的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
US11179322B2 (en) 2018-07-10 2021-11-23 Novocure Gmbh Methods and compositions for treating tumors with TTFields and sorafenib
WO2018211336A2 (en) 2018-09-07 2018-11-22 Alvogen Malta Operations (Row) Ltd Solid dosage form containing sorafenib tosylate
US20210401859A1 (en) 2018-11-01 2021-12-30 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CN110156671A (zh) * 2019-06-06 2019-08-23 杭州中美华东制药有限公司 新型的索拉非尼共晶及其制备方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4410190A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli 3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
WO1997046526A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
RS49597B (sr) 1996-09-23 2007-06-04 Eli Lilly And Company, Olanzapin dihidrat d
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US6344476B1 (en) * 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US7329670B1 (en) * 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) * 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
EP1158985B1 (en) * 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
WO2000042012A1 (en) * 1999-01-13 2000-07-20 Bayer Corporation φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
SI1450799T1 (sl) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aril secninske spojine v kombinaciji z drugimi citostaticnimi ali citotoksicnimi sredstvi za zdravljenje cloveskih rakov
GB0129876D0 (en) 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20030216396A1 (en) * 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
PT1478358E (pt) * 2002-02-11 2013-09-11 Bayer Healthcare Llc Tosilato de sorafenib para o tratamento de doenças caracterizadas por angiogénese anormal
AU2003209118A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
GB0203412D0 (en) 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
CN1716417A (zh) 2002-03-29 2006-01-04 索尼株式会社 光盘识别装置和方法、光盘记录装置和光盘再现装置
EP1504047B1 (en) * 2002-05-03 2007-12-12 Janssen Pharmaceutica N.V. Polymeric microemulsions
US7351534B2 (en) * 2003-01-27 2008-04-01 Oregon Health & Sciences University Gene mutation associated with age-related macular degeneration
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US7378233B2 (en) * 2003-04-12 2008-05-27 The Johns Hopkins University BRAF mutation T1796A in thyroid cancers
JP2007511203A (ja) * 2003-05-20 2007-05-10 バイエル、ファーマシューテイカルズ、コーポレイション キナーゼ阻害活性を有するジアリール尿素
DE602004010407T2 (de) * 2003-07-23 2008-10-16 Bayer Pharmaceuticals Corp., West Haven Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE517885T1 (de) * 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
CN101048140B (zh) * 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物
KR20090018224A (ko) 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
EP1797037B1 (en) 2004-09-29 2014-12-17 Bayer HealthCare LLC Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
US7271763B2 (en) * 2005-03-03 2007-09-18 The United States Of America As Represented By The Secretary Of The Army Hybrid-phased communication array
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
US8329408B2 (en) * 2005-10-31 2012-12-11 Bayer Healthcare Llc Methods for prognosis and monitoring cancer therapy
CA2627873A1 (en) * 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
AU2006312714A1 (en) * 2005-11-10 2007-05-18 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating pulmonary hypertension
US20100144749A1 (en) * 2005-11-14 2010-06-10 Scott Wilhelm Treatment of cancers with acquired resistance to kit inhibitors
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100063112A1 (en) * 2006-11-09 2010-03-11 Bayer Schering Pharma Aktiengesellschaft Polymorph iii of 4-[4-(amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide
US20100113533A1 (en) * 2006-11-14 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
WO2008079968A1 (en) * 2006-12-20 2008-07-03 Bayer Healthcare Llc 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl) phenyl]-1h-pyrazol-5-yl } carbamoyl)-amino] -3-fluorophenoxy} -n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
US8680124B2 (en) * 2007-01-19 2014-03-25 Bayer Healthcare Llc Treatment of cancers with acquired resistance to kit inhibitors
CA2675979A1 (en) * 2007-01-19 2008-07-24 Bayer Healthcare Llc Treatment of cancers having resistance to chemotherapeutic agents
EP2231612A1 (en) * 2008-01-17 2010-09-29 Sicor, Inc. Polymorph form iii of sorafenib tosylate, sorafenib tosylate methanol solvate and sorafenib tosylate ethanol solvate, and processes for preparation thereof
US20110257035A1 (en) * 2008-10-21 2011-10-20 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
AR081060A1 (es) * 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
JP2013531067A (ja) * 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
PE20140165A1 (es) * 2010-10-01 2014-02-26 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino)arilsulfonamida
EA201400064A1 (ru) 2011-06-28 2014-05-30 Байер Хелфкеэ Ллк Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
JP2014518232A (ja) 2011-06-28 2014-07-28 バイエル・ヘルスケア・エルエルシー ソラフェニブを含有する眼科用局所医薬組成物

Also Published As

Publication number Publication date
EP1797038A1 (en) 2007-06-20
MA28880B1 (fr) 2007-09-03
AU2005289100B2 (en) 2011-11-03
IL181734A (en) 2015-10-29
CA2581843C (en) 2012-05-15
PE20142042A1 (es) 2014-12-03
NZ553804A (en) 2010-07-30
DK1797038T3 (da) 2012-09-03
CA2581843A1 (en) 2006-04-06
CN101065360B (zh) 2011-08-03
TWI382016B (zh) 2013-01-11
JP2008514658A (ja) 2008-05-08
KR20100061869A (ko) 2010-06-09
NO20071508L (no) 2007-06-22
SG155996A1 (en) 2009-10-29
PL1797038T3 (pl) 2012-11-30
HK1114605A1 (en) 2008-11-07
AU2005289100A1 (en) 2006-04-06
KR101239489B1 (ko) 2013-03-06
UA91520C2 (en) 2010-08-10
JP5215666B2 (ja) 2013-06-19
US20090215833A1 (en) 2009-08-27
IL181734A0 (en) 2007-07-04
UY29144A1 (es) 2006-04-28
CU20070068A7 (es) 2010-01-22
WO2006034797A1 (en) 2006-04-06
KR20070058537A (ko) 2007-06-08
GT200500270A (es) 2006-04-25
ES2387812T3 (es) 2012-10-02
KR20090018224A (ko) 2009-02-19
NO344272B1 (no) 2019-10-21
SI1797038T1 (sl) 2012-10-30
TW200626552A (en) 2006-08-01
EP1797038B1 (en) 2012-06-13
KR20130004385A (ko) 2013-01-09
CN101065360A (zh) 2007-10-31
PT1797038E (pt) 2012-08-14
PE20100445A1 (es) 2010-07-04
KR101381454B1 (ko) 2014-04-04
ECSP077356A (es) 2007-04-26
JP2013100302A (ja) 2013-05-23
BRPI0515946A (pt) 2008-08-12
MY176929A (en) 2020-08-27
PE20060699A1 (es) 2006-08-12
US8877933B2 (en) 2014-11-04
ZA200702510B (en) 2008-07-30
HRP20120662T1 (hr) 2012-09-30
HN2005000722A (es) 2010-08-19
AR051301A1 (es) 2007-01-03

Similar Documents

Publication Publication Date Title
CY1113598T1 (el) Θερμοδυναμικα σταθερη μορφη του αλατος τολουολοσουλφονικου οξεος βαυ 43-9006
CY1114637T1 (el) 4-[4-({[4-χλωρο-3-(τριφθορομεθυλο)φαινυλο)]καρβαμοϋλ}αμινο)-3-φθοροφαινοξυ]-ν-μεθυλοπυριδινο-2-καρβοξαμιδιο μονοϋδρικο
CU20070069A7 (es) Proceso para la preparación de 4-{4-[cloro-3-(trifluorometil)fenil]amino}carbonil)amino]fenoxi}-n-metilpiridina-2-carboxamida
AR057467A1 (es) Sales de 4- metil-n-(3-(4-metilimidazol-1-il)-5- trifluorometil- fenil)-3- (4- metil- imidazol-1-il)-5- trifluorometil - fenil)-3-(4- piridin -3- il pirimidin-2- lamino ) - benzamida. metodo de preparacion y composiciones farmaceuticas
PT998473E (pt) Modificacao da forma de cristal de um derivado de n-fenil-2-pirimidinoamina processos para a sua preparacao e sua utilizacao
NO20081482L (no) Delta- og epsilon-krystallformer for imatinibmesylat
CY1112115T1 (el) Παραγωγα φαινοξυοξικου οξεος χρησιμα για τη θεραπευτικη αντιμετωπιση ασθενειων του αναπνευστικου
NO20080820L (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
UA87865C2 (en) Hydrates and polymorphs of 4-[[(7r)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-4-6-oxo-2-piperidinyl]amino]-3-methoxy-n-(1-methyl-4-piperidinyl)-benzamide, methods for the production thereof, and use thereof as medicaments
CY1110775T1 (el) Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης
CY1109013T1 (el) Νεα 4,4΄-διθειοδις-(3-αμινοβουτανιο-1-σουλφονικα) παραγωγα και συνθεσεις που τα περιεχουν
RS52354B (en) PHARMACEUTICAL MIXTURES WHICH HAVE ADVANCED DISSOLUTION PROFILES FOR Slightly Soluble Medicines
IS2712B (is) Notkun týrósínkínasatálma til að meðhöndla sykursýki
BRPI0411168A (pt) composição para o tratamento dos cabelos, usos de uma composição e método de tratamento dos cabelos
CY1110212T1 (el) Χαμηλης υγροσκοπικοτητας αριπιπραζολη ως φαρμακευτικη ουσια και μεθοδοι για την παρασκευη της
ATE313528T1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen
ATE313529T1 (de) 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen
DOP2005000184A (es) Forma termodinamicamente estable de una sal tosilato
TH98396A (th) 4-[4-({[4-คลอโร-3-(ไตรฟลูออโรเมทธิล)ฟีนิล]คาร์บาโมอิล}อะมิโน)-3-ฟลูออโรฟีนอกซี]-n-เมทธิลไพริดีน-2-คาร์บอกซาไมด์ โมโนไฮเดรท
TH81349A (th) รูปแบบเสถียรทางเธอร์โมไดนามิกของเกลือโทซิเลต
ATE326970T1 (de) Verwendung von 4-(4-methylpiperazin-1-ylmethyl)-n 4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl benzamid zur behandlung von seminomen
TH87627A (th) เกลือของ 4-เมทธิล-n-[3-(4-เมทธิล-อิมิดาโซล-1-อิล)-5-ไทรฟลูออโรเมทธิล-เฟนิล]-3-(4-ไพริดิน-3-อิล-ไพริมิดิน-2-อิลอะมิโน)-เบนซาไมด์
FR2863497B1 (fr) Nouvelles compositions pharmaceutiques et/ou dietetiques contre le stress
ITMI20040145A1 (it) L-moprololo lpiu' tartrato
BRPI0519029A2 (pt) composto, uso do mesmo, e, composiÇço farmacÊutica